ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Prof Jérémie Calais presents a talk on FAP-targeted molecular radiotherapy in cancer patients.
He begins by explaining that the FAP (fibroblast activation protein) target is a stromal target and how this can be used for imaging.
Dr Calais goes on to compare FAP-targeted MRT (molecular radiotherapy) with PSMA MRT, highlighting that FAP-targeted MRT is not quite at the full potential yet.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ASCO 2024: Lung cancer highlights
Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy
ASCO 2024: Advances in NSCLC
Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI
Adjuvant radiotherapy has no benefit following radical prostatectomy
Choosing Wisely in radiology Tanzania
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital